237 related articles for article (PubMed ID: 35879777)
1. Co-expression of TNF receptors 1 and 2 on melanomas facilitates soluble TNF-induced resistance to MAPK pathway inhibitors.
Sander CA; Rush EA; Shi J; Arantes LMRB; Tesi RJ; Ross MA; Calderon MJ; Watkins SC; Kirkwood JM; Ferris RL; Butterfield LH; Vujanovic L
J Transl Med; 2022 Jul; 20(1):331. PubMed ID: 35879777
[TBL] [Abstract][Full Text] [Related]
2. Fundamentally different roles of neuronal TNF receptors in CNS pathology: TNFR1 and IKKβ promote microglial responses and tissue injury in demyelination while TNFR2 protects against excitotoxicity in mice.
Papazian I; Tsoukala E; Boutou A; Karamita M; Kambas K; Iliopoulou L; Fischer R; Kontermann RE; Denis MC; Kollias G; Lassmann H; Probert L
J Neuroinflammation; 2021 Sep; 18(1):222. PubMed ID: 34565380
[TBL] [Abstract][Full Text] [Related]
3. A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of
Aloia A; Müllhaupt D; Chabbert CD; Eberhart T; Flückiger-Mangual S; Vukolic A; Eichhoff O; Irmisch A; Alexander LT; Scibona E; Frederick DT; Miao B; Tian T; Cheng C; Kwong LN; Wei Z; Sullivan RJ; Boland GM; Herlyn M; Flaherty KT; Zamboni N; Dummer R; Zhang G; Levesque MP; Krek W; Kovacs WJ
Clin Cancer Res; 2019 Nov; 25(22):6852-6867. PubMed ID: 31375515
[TBL] [Abstract][Full Text] [Related]
4. A TRAF2 binding independent region of TNFR2 is responsible for TRAF2 depletion and enhancement of cytotoxicity driven by TNFR1.
Cabal-Hierro L; Artime N; Iglesias J; Prado MA; Ugarte-Gil L; Casado P; Fernández-García B; Darnay BG; Lazo PS
Oncotarget; 2014 Jan; 5(1):224-36. PubMed ID: 24318359
[TBL] [Abstract][Full Text] [Related]
5. Plasma proteome alterations by MAPK inhibitors in BRAF
Babačić H; Eriksson H; Pernemalm M
Neoplasia; 2021 Aug; 23(8):783-791. PubMed ID: 34246984
[TBL] [Abstract][Full Text] [Related]
6. Distinct contributions of TNF receptor 1 and 2 to TNF-induced glomerular inflammation in mice.
Taubitz A; Schwarz M; Eltrich N; Lindenmeyer MT; Vielhauer V
PLoS One; 2013; 8(7):e68167. PubMed ID: 23869211
[TBL] [Abstract][Full Text] [Related]
7. Regulation of CEACAM1 Protein Expression by the Transcription Factor ETS-1 in BRAF-Mutant Human Metastatic Melanoma Cells.
Kfir-Elirachman K; Ortenberg R; Vizel B; Besser MJ; Barshack I; Schachter J; Nemlich Y; Markel G
Neoplasia; 2018 Apr; 20(4):401-409. PubMed ID: 29558679
[TBL] [Abstract][Full Text] [Related]
8. TNFR2 increases the sensitivity of ligand-induced activation of the p38 MAPK and NF-κB pathways and signals TRAF2 protein degradation in macrophages.
Ruspi G; Schmidt EM; McCann F; Feldmann M; Williams RO; Stoop AA; Dean JL
Cell Signal; 2014 Apr; 26(4):683-90. PubMed ID: 24378531
[TBL] [Abstract][Full Text] [Related]
9. Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.
Dankner M; Lajoie M; Moldoveanu D; Nguyen TT; Savage P; Rajkumar S; Huang X; Lvova M; Protopopov A; Vuzman D; Hogg D; Park M; Guiot MC; Petrecca K; Mihalcioiu C; Watson IR; Siegel PM; Rose AAN
Clin Cancer Res; 2018 Dec; 24(24):6483-6494. PubMed ID: 29903896
[TBL] [Abstract][Full Text] [Related]
10. Generation of mouse macrophages expressing membrane-bound TNF variants with selectivity for TNFR1 or TNFR2.
Shibata H; Abe Y; Yoshioka Y; Nomura T; Sato M; Kayamuro H; Kawara T; Arita S; Furuya T; Nagano K; Yoshikawa T; Kamada H; Tsunoda S; Tsutsumi Y
Cytokine; 2010 Apr; 50(1):75-83. PubMed ID: 20045350
[TBL] [Abstract][Full Text] [Related]
11. A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in
Usta D; Sigaud R; Buhl JL; Selt F; Marquardt V; Pauck D; Jansen J; Pusch S; Ecker J; Hielscher T; Vollmer J; Sommerkamp AC; Rubner T; Hargrave D; van Tilburg CM; Pfister SM; Jones DTW; Remke M; Brummer T; Witt O; Milde T
Mol Cancer Ther; 2020 Aug; 19(8):1736-1750. PubMed ID: 32451331
[TBL] [Abstract][Full Text] [Related]
12. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.
Konieczkowski DJ; Johannessen CM; Abudayyeh O; Kim JW; Cooper ZA; Piris A; Frederick DT; Barzily-Rokni M; Straussman R; Haq R; Fisher DE; Mesirov JP; Hahn WC; Flaherty KT; Wargo JA; Tamayo P; Garraway LA
Cancer Discov; 2014 Jul; 4(7):816-27. PubMed ID: 24771846
[TBL] [Abstract][Full Text] [Related]
13. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
[TBL] [Abstract][Full Text] [Related]
14. A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma.
Vashisht Gopal YN; Gammon S; Prasad R; Knighton B; Pisaneschi F; Roszik J; Feng N; Johnson S; Pramanik S; Sudderth J; Sui D; Hudgens C; Fischer GM; Deng W; Reuben A; Peng W; Wang J; McQuade JL; Tetzlaff MT; Di Francesco ME; Marszalek J; Piwnica-Worms D; DeBerardinis RJ; Davies MA
Clin Cancer Res; 2019 Nov; 25(21):6429-6442. PubMed ID: 31439581
[TBL] [Abstract][Full Text] [Related]
15. GJB5 association with BRAF mutation and survival in cutaneous malignant melanoma.
Scatolini M; Patel A; Grosso E; Mello-Grand M; Ostano P; Coppo R; Vitiello M; Venesio T; Zaccagna A; Pisacane A; Sarotto I; Taverna D; Poliseno L; Bergamaschi D; Chiorino G
Br J Dermatol; 2022 Jan; 186(1):117-128. PubMed ID: 34240406
[TBL] [Abstract][Full Text] [Related]
16. Both internalization and AIP1 association are required for tumor necrosis factor receptor 2-mediated JNK signaling.
Ji W; Li Y; Wan T; Wang J; Zhang H; Chen H; Min W
Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2271-9. PubMed ID: 22743059
[TBL] [Abstract][Full Text] [Related]
17. Membrane tumor necrosis factor (TNF) induces p100 processing via TNF receptor-2 (TNFR2).
Rauert H; Wicovsky A; Müller N; Siegmund D; Spindler V; Waschke J; Kneitz C; Wajant H
J Biol Chem; 2010 Mar; 285(10):7394-404. PubMed ID: 20038584
[TBL] [Abstract][Full Text] [Related]
18. Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbouring BRAF
Fu H; Cheng L; Sa R; Jin Y; Chen L
J Cell Mol Med; 2020 Mar; 24(6):3336-3345. PubMed ID: 31970877
[TBL] [Abstract][Full Text] [Related]
19. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
20. Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation.
Song C; Piva M; Sun L; Hong A; Moriceau G; Kong X; Zhang H; Lomeli S; Qian J; Yu CC; Damoiseaux R; Kelley MC; Dahlman KB; Scumpia PO; Sosman JA; Johnson DB; Ribas A; Hugo W; Lo RS
Cancer Discov; 2017 Nov; 7(11):1248-1265. PubMed ID: 28864476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]